MEDVi review: read the month-two price before the ads win
Verdict
MEDVi is one of the most heavily advertised compounded-GLP-1 programs, and the ads lead with $179/month — which is the first month only. Ongoing refills are $299/month for compounded semaglutide and $399/month for tirzepatide. That makes it more expensive month-over-month than Mochi (~$178 all-in) and SkinnyRx ($199), and MEDVi carries the most serious compliance mark in the group: an FDA warning letter issued February 20, 2026.
$179 intro → $299 ongoing FDA warning letter (Feb 2026) Compounded meds — not FDA-approved Fast async signup
What it actually costs
| Item | First month | Ongoing | Notes |
|---|---|---|---|
| Compounded semaglutide | $179 | $299/mo | Bundled — no separate membership fee on compounded plans |
| Compounded tirzepatide | $279 | $399/mo | |
| Branded Wegovy/Zepbound path | Med cost + $99/mo membership | Manufacturer pricing on top of a monthly fee — usually beaten by going manufacturer-direct yourself | |
Compare: Mochi is ~$178/month every month (semaglutide, all-in) and SkinnyRx starts at $199 bundled. MEDVi's ongoing $299 only wins on convenience if its intake or shipping matters more to you than $100–120/month.
Availability and sign-up
- Not available in North Dakota.
- Video visit required first in KS, IN, MS, NM, OK, WV; everywhere else, async questionnaire + photo ID with ~24-hour provider review.
- Alabama and California: injectables only (no tablets).
- Cancellation: at least 72 hours before the next billing date; full refund only within the first 72 hours if nothing was shipped, or if the provider disqualifies you. Billing and refund friction is the most common consumer complaint we found.
The FDA warning letter, plainly
On February 20, 2026, the FDA issued MEDVi LLC warning letter #721455, citing misbranding — MEDVi-labeled compounded drugs that implied MEDVi itself was the compounding pharmacy — and marketing claims comparing its compounded products to FDA-approved drugs. MEDVi has attributed some of the flagged marketing to an affiliate-run website. Either way, the letter is public, recent, and unresolved as far as our research could establish, and it sits alongside the FDA's March 2026 sweep of 30 warning letters to compounded-GLP-1 telehealth marketers. A warning letter is not a shutdown order — MEDVi is operating, is LegitScript-certified, and holds a 4.4 Trustpilot rating — but if regulatory cleanliness matters to you, other providers in our comparison don't carry this mark.
Where MEDVi wins
- Fast async approval (~24 hours) in most states
- Bundled pricing — no separate membership line on compounded plans
- Both semaglutide and tirzepatide, injection or tablet forms
- Strong first-month intro price if you're testing tolerability
Where it doesn't
- Ongoing price is the highest of the major compounded programs
- FDA warning letter, February 2026
- Refund/cancellation terms are tight (72-hour windows)
- State carve-outs: no ND; video-first in 6 states; injectables-only in AL/CA
- Compounded meds are not FDA-approved
Who should pick MEDVi
Honestly, at $299/month ongoing, not many people — unless the specific formulation you want (e.g., tablets, where available) or the fast intake is decisive. If you've settled on a compounded program, Mochi costs ~$120/month less with better terms; if you want FDA-approved medication, the manufacturer direct-pay programs start at $149/month.
Back to full comparison Check MEDVi's current pricing